Circulating basophils in patients with type IIb autoimmune chronic spontaneous urticaria have a lower histamine content

Katrine Baumann*, Jennifer Astrup Sørensen, Ditte G Zhang, Misbah N Ghazanfar, Per Stahl Skov, Anders Woetmann, Simon Francis Thomsen

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

7 Downloads (Pure)

Abstract

Background: Patients suffering from chronic spontaneous urticaria (CSU) are typically classified as type I or type IIb autoimmune CSU, but further patient stratification is hindered by the lack of biomarkers. Objectives: We investigated whether the histamine content of individual basophils differ between patient subtypes in CSU to evaluate its potential as a biomarker. Methods: A total of 101 patients diagnosed with CSU were included in the study. The histamine content per circulating basophil was derived from the basophil count in peripheral blood and levels of total cellular blood histamine. These measures, together with results from the serum-induced basophil histamine release assay (s-BHRA), were correlated to information on demographics, clinical characteristics, patient reported outcomes and laboratory analyses. Results: The histamine content per basophil was significantly different between s-BHRA negative and -positive patients (0.175 vs. 1.40 pg/cell, p < 0.001) and showed a significant negative correlation to the degree of basophil activation in s-BHRA (ρ = −0.209, p = 0.036). Furthermore, the amount of histamine in individual basophils was found to be significantly correlated with levels of total cellular blood histamine (ρ = 0.376, p < 0.001), eosinophil counts (ρ = 0.205, p = 0.040), levels of thyroid stimulating hormone (ρ = −0.246, p = 0.014) and titre of antibodies against thyroid peroxidase (ρ = −0.216, p = 0.031) and thyroglobulin (ρ = −0.203, p = 0.044). Conclusions: Low content of intracellular histamine in circulating basophils is associated with known markers of type IIb autoimmune CSU. Further studies are required to assess whether the amount of histamine in basophils can be used to monitor or predict response to treatment in patients.

OriginalsprogEngelsk
TidsskriftJEADV Clinical Practice
Vol/bind3
Udgave nummer2
Sider (fra-til)658-663
ISSN2768-6566
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
Katrine Baumann was supported by the BRIDGE–Translational Excellence Programme (bridge.ku.dk) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation. Grant agreement no. NNF20SA0064340 (2021 fellows).

Publisher Copyright:
© 2024 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Citationsformater